Bayer Cropscience Ltd.

“Bayer CropScience India is a zero-debt, high-ROCE branded agrochemical franchise in a structurally growing Indian market, but the investment case is undermined by a 31x earnings multiple that prices in 14–17% growth the competitive and reinvestment dynamics cannot support, a narrowing moat as generics commoditize legacy chemistries, and a permanent structural discount from Bayer AG's 71% majority control which extracts value via royalties and RPTs above the minority's reach. The 10-year base case return of 1.8–2.2x (~6–8% CAGR) does not justify current capital allocation when faster-compounding peers with better minority alignment are available. Monitor for a 25–30% price correction to the INR 3,200–3,500 range before initiating a position.”